Dr. Rayne H. Rouce
Claim this profileTexas Children's Hospital
Studies Acute Lymphoblastic Leukemia
Studies Non-Hodgkin's Lymphoma
9 reported clinical trials
20 drugs studied
Area of expertise
1Acute Lymphoblastic Leukemia
CD7 positive
CD5 positive
CD19 positive
2Non-Hodgkin's Lymphoma
EBV positive
CD7 positive
CD5 positive
Affiliated Hospitals
Clinical Trials Rayne H. Rouce is currently running
CAR T-Cell Therapy
for Leukemia and Lymphoma
Patients with relapsed or refractory leukemia or lymphoma are often refractory to further chemotherapy. In this study, the investigators will attempt to use T cells obtained directly from the patient, which can be genetically engineered to express a chimeric antigen receptor (CAR). The CAR used in this study can recognize CD22, a protein expressed on the surface of leukemia and lymphoma cells. The phase 1 part of this study will determine the safety and appropriate dose level of these CAR T cells, and the phase 2 part of the study will determine how effective this CAR T cell therapy is. Both patients who have never had prior CAR T cell therapy and those who have had prior CAR T cell therapy may be eligible to participate in this study.
Recruiting1 award Phase 1 & 215 criteria
CAR T-Cell Therapy
for Blood Cancer
Patients eligible for this study have a type of blood cancer called T-cell leukemia or lymphoma (lymph gland cancer). The body has different ways of fighting infection and disease. This study combines two different ways of fighting disease with antibodies and T cells. Antibodies are types of proteins that protect the body from bacterial and other diseases. T cells, or T lymphocytes, are special infection-fighting blood cells that can kill other cells including tumor cells. Both antibodies and T cells have been used to treat cancer; they have shown promise, but have not been strong enough to cure most patients. T cells can kill tumor cells but there normally are not enough of them to kill all the tumor cells. Some researchers have taken T cells from a person's blood, grown more of them in the laboratory and then given them back to the person. The antibody used in this study is called anti-CD7. This antibody sticks to T-cell leukemia or lymphoma cells because of a substance on the outside of these cells called CD7. CD7 antibodies have been used to treat people with T-cell leukemia and lymphoma. For this study, anti-CD7 has been changed so that instead of floating free in the blood it is now joined to the T cells. When an antibody is joined to a T cell in this way it is called a chimeric receptor. In the laboratory, investigators have also found that T cells work better if they also add proteins that stimulate T cells, such as one called CD28. Adding the CD28 makes the cells grow better and last longer in the body, thus giving the cells a better chance of killing the leukemia or lymphoma cells. In this study, investigators attach the CD7 chimeric receptor with CD28 added to it to T cells. Investigators will then test how long the cells last. These CD7 chimeric receptor T cells with CD28 are investigational products not approved by the Food and Drug Administration.
Recruiting1 award Phase 1
More about Rayne H. Rouce
Clinical Trial Related6 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Rayne H. Rouce has experience with
- Fludarabine
- Cyclophosphamide
- MABEL CTLs
- CD7.CAR/28zeta CAR T Cells
- Allogeneic CD5.CAR/28zeta CAR T Cells
- Autologous CD5.CAR/28zeta CAR T Cells
Breakdown of trials Rayne H. Rouce has run
Acute Lymphoblastic Leukemia
Non-Hodgkin's Lymphoma
Lymphoma
Central Nervous System Hodgkin Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Rayne H. Rouce specialize in?
Rayne H. Rouce focuses on Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma. In particular, much of their work with Acute Lymphoblastic Leukemia has involved CD7 positive patients, or patients who are CD5 positive.
Is Rayne H. Rouce currently recruiting for clinical trials?
Yes, Rayne H. Rouce is currently recruiting for 3 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Rayne H. Rouce has studied deeply?
Yes, Rayne H. Rouce has studied treatments such as Fludarabine, Cyclophosphamide, MABEL CTLs.
What is the best way to schedule an appointment with Rayne H. Rouce?
Apply for one of the trials that Rayne H. Rouce is conducting.
What is the office address of Rayne H. Rouce?
The office of Rayne H. Rouce is located at: Texas Children's Hospital, Houston, Texas 77030 United States. This is the address for their practice at the Texas Children's Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.